ウイルスポリメラーゼインヒビター

Japanese Patent JP2005504030

A

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, N R 1 , or C R 1 , wherein R 1 is defined herein; ----- represents either a single or a double bond; R 2 is selected from: H, halogen, R 21 , O R 21 , S R 21 , COO R 21 , SO 2 N( R 22 ) 2 , N( R 22 ) 2 , , CON( R 22 ) 2 , N R 22 C(O) R 22 or N R 22 C(O)N R 22 wherein R 21 and each R 22 is defined herein; B is N R 3 or C R 3 , with the proviso that one of A or B is either C R 1 or C R 3 , wherein R 3 is defined herein; K is N or C R 4 , wherein R 4 is defined herein; L is N or C R 5 , wherein R 5 has the same definition as R 4 ; M is N or C R 7 , wherein R 7 has the same definition as R 4 ; Y 1 is O or S; Z is N( R 6a ) R 6 or O R 6 , wherein R 6a is H or alkyl or N R 61 R 62 wherein R 61 and R 62 are defined herein; and R 6 is H, alkyl, cycloalkyl, alkenyl, Het , alkyl-aryl, alkyl- Het ; or R 6 is wherein R 7 and R 8 and Q are as defined herein; Y 2 is O or S; R 9 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl, aryl, Het , (C 1-6 )alkyl-aryl or (C 1-6 )alkyl- Het , all of which optionally substituted with R 90 ; or R 9 is covalently bonded to either of R 7 or R 8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.

WO/2003/043618	AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE
JP2013155209	METHODS AND COMPOSITIONS FOR REDUCTION OF SIDE EFFECTS OF THERAPEUTIC TREATMENTS

Beaulieu Pierre Louis
Fazar Gururezu
Kukori George
Jolicourt Eric
Girard James
Pupal Marc-Andre
Lancourt Jean

JP2003515499A

February 10, 2005

July 18, 2002

Click for automatic bibliography generation  

Boehringer Ingelheim (Canada) Limited

A61K31/13; A61K31/381; A61K31/404; A61K31/405; A61K31/4184; A61K31/422; A61K31/427; A61K31/428; A61K31/437; A61K31/443; A61K31/4436; A61K31/4439; A61K31/454; A61K31/4545; A61K31/4709; A61K31/497; A61K31/506; A61K31/53; A61K31/5377; A61K31/7052; A61K38/21; A61K45/00; A61P31/12; A61P31/14; A61P37/02; A61P43/00; C07D209/08; C07D209/14; C07D209/20; C07D209/30; C07D209/42; C07D333/62; C07D401/04; C07D401/06; C07D401/12; C07D401/14; C07D403/04; C07D405/04; C07D405/12; C07D405/14; C07D407/14; C07D409/04; C07D409/14; C07D413/04; C07D413/14; C07D417/04; C07D417/12; C07D417/14; C07D471/02; C07D471/04; C07D491/02; C07D498/02; C07H19/056; C07D; (IPC1-7): C07D209/08; A61K31/13; A61K31/381; A61K31/404; A61K31/4184; A61K31/422; A61K31/427; A61K31/437; A61K31/443; A61K31/4436; A61K31/4439; A61K31/506; A61K31/7052; A61K38/21; A61K45/00; A61P31/14; A61P43/00; C07D209/30; C07D209/42; C07D333/62; C07D401/04; C07D403/04; C07D405/04; C07D409/04; C07D413/04; C07D417/04; C07D471/04

Sadao Kumakura
Nobuo Ogawa
Atsushi Hakoda
Kenji Asai
Koji Hirayama

Previous Patent: 犬の好ましくない行動を改善するためのＮＫ−１受容体アンタゴニストの�...

Next Patent: Ｃ−ＪＵＮ−Ｎ−末端キナーゼ（ＪＮＫ）インヒビターとしてのアリール�...